Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Larry Lowe has suffered excruciating symptoms since he received the vaccine in 2021 and his condition is ‘only going to get ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...

Former Pfizer Inc. executives Ian Read and Frank D’Amelio have decided “not to be involved” in Starboard Value’s activist ...

Activist investor Starboard Value claims the pharma giant’s former CEO and CFO were “threatened” into backing current ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...